Angela J. Yoon was named director of the MUSC Hollings Cancer Center Biorepository and Tissue Analysis Shared Resource, effective Dec. 1; she will oversee a growing collection of cancer-associated biospecimens that allow researchers to translate Biological discoveries into prevention, diagnosis and treatment of cancer.
The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.
